Despite advances in the treatment of asthma, optimization of symptom control remains an unmet need in many patients. These patients, labeled severe asthma, are responsible for a substantial fraction of the disease burden. In these patients, research is needed to define the cellular and molecular pathways contributing to disease which in large part are refractory to corticosteroid treatment. The causes of steroid-resistant asthma are multifactorial and result from complex interactions of genetics, environmental factors, and innate and adaptive immunity. Adaptive immunity, addressed here, integrates the activities of distinct T-cell subsets and by definition is dynamic and responsive to an ever-changing environment and the influences of epigenetic modifications. These T-cell subsets exhibit different susceptibilities to the actions of corticosteroids and, in some, corticosteroids enhance their functional activation.
| INTRODUCTION
Asthma is a complex syndrome characterized by altered airway function and airway inflammation. Over the last several decades, there has been significant progress in both the understanding and treatment of asthma. The introduction of inhaled corticosteroids, avoiding the many adverse events of systemic corticosteroids, significantly impacted the quality of life of asthmatics with significant reductions in asthma mortality and morbidity, as well as the need for hospitalization and urgent care visits. Despite these advances, a number of issues remain unresolved and unmet needs for asthmatics persist. It is estimated that 10%-15% of asthmatics remain uncontrolled on what is considered optimum therapy, and upwards of 40% of asthmatics may show little to no improvement (even deterioration) of lung function on high doses of inhaled corticosteroids. [1] [2] [3] The efficacy of corticosteroids in asthma likely occurs at several levels, primarily reducing inflammation and edema. Effects on smooth muscle contractility or
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airway remodeling are less apparent. The anti-inflammatory effects are mediated by targeting steroid-sensitive (SS) cells, cells which undergo apoptosis or alter functional programs when exposed to corticosteroids. Since corticosteroids may not be equally effective in all patients, it is likely that other cell types and pathways contributing to asthma are not SS and are major contributors to steroid-resistant (SR)
asthma. Examples of corticosteroid-sensitive cells that are implicated in asthma pathogenesis are CD4 + T cells and eosinophils, while neutrophils and CD8 + T cells have been shown to be insensitive to corticosteroids. Given the efficacy of corticosteroids in a large proportion of asthmatics, the development of novel therapeutics has been to address the needs of patients whose asthma is uncontrolled or requires high doses of corticosteroids. In addition, since corticosteroids have little disease-modifying activity and are only effective when taken, 4 targeting pathways or mediators contributing to disease progression are important objectives. Corticosteroids may also have a limited role in preventing asthma exacerbations, further suggesting that the triggers of exacerbation may involve cells and pathways that are less responsive to corticosteroids. Different triggers of asthma exacerbation result in diverse immune-inflammatory outcomes, including accumulation of different inflammatory cells [5] [6] [7] [8] [9] [10] and pathways that exhibit differential steroid responsiveness (Table 1) .
Central to these issues is the large variety of T-lymphocyte subsets implicated in asthma pathobiology and the integration of adaptive and innate immunity leading to airway dysfunction and inflammation.
In this review, we will consider the individual contributions of several distinct T-cell subsets, their integration into pathology-driving circuits, the pathways activated by different asthma triggers, and the identification of pathways that are SS and those which remain unaffected by corticosteroids contributing to severe asthma. In addition to infiltrating and resident T lymphocytes, airway structural cells participate in the inflammatory responses releasing important mediators that regulate T-cell subsets and innate lymphoid cell (ILC) responses. Oxidative stress is an important regulator of airway inflammatory responses, especially in severe asthma associated with increased levels of reactive oxygen species (ROS) and reduced anti-oxidant responses. 11, 12 The increased levels of ROS contribute in different ways to the chronic inflammatory responses, airway hypercontractility, and corticosteroid insensitivity. [13] [14] [15] This immunoinflammatory complexity positions asthma as a syndrome with many overlapping phenotypes when clinical and physiological parameters are considered. Clustering of asthma phenotypes based on these parameters has had some benefit in furthering our understanding of the significant heterogeneity of asthma. However, only by understanding the underlying mechanisms and pathways (endotypes) involved will we advance personalized treatment. Defining asthma clusters based on differentially expressed genes appears more promising to capture the diverse pathways of asthma pathobiology that could lead to identification of important targets for therapy and offer insights toward achieving personalized medicine. [16] [17] [18] This approach has been used to identify genes from sputum cells that associated pathway-based transcriptomic clusters to clinically important features of asthma. 19 A major challenge faced in a clustering approach is the heterogeneity of the disease, not only between patients but also in the same patient at different stages of their disease. Based on clinical and physiological parameters, the stability of a patient remaining in the same asthma cluster over time is controversial. 20, 21 This may not be surprising given the number of triggers resulting in an asthma exacerbation.
These individual triggers have the capacity to activate distinct pathways characterized by unique patterns of inflammatory cell accumulation and the response to corticosteroids (Table 1) . Notwithstanding the important gene-environment interactions that govern these outcomes, epigenetic mechanisms link gene regulation to these environmental triggers. Important epigenetic marks that govern the distinct stages of asthma from inception to maintenance, to exacerbation, and to resolution are in large part translated to T-cell subset function and cytokine release. Understanding these intricate and dynamic interactions between functionally activated T-cell subsets and asthma pathophysiology requires well-characterized experimental models and longitudinal cellular, molecular, genetic, and clinical investigations, with the ultimate goal of identifying novel therapeutic approaches.
| THE ROLE OF CD4 + T CELLS IN PATIENTS WITH ASTHMA
For several decades, asthma has been considered a T-helper 2 (Th2)-driven inflammatory disease, characterized by eosinophilic inflammation, Th2 cytokine production [ie, interleukin-4 (IL-4), IL-5, and IL-13], and airway hyperresponsiveness (AHR). 22, 23 In the earliest studies, type 2 cytokine-producing CD4 + T cells were identified in the bronchoalveolar lavage (BAL) fluid and airway tissue of asthmatics. 24 In mice, the transfer of Th2 cells was sufficient to induce airway eosinophilia and AHR. 25, 26 Naive T cells can, under different conditions, differentiate into Th1, Th2, Th9, Th17, or T regulatory (Treg) cells, each characterized by the release of distinct cytokine profiles and effector functions. Each of these T-cell subsets has been associated with T A B L E 1 Asthma pathogenesis allergic inflammation indicating the complex fate decisions and multifaceted involvement in disease pathology. 27 During differentiation, each of the T-cell subsets is subject to the cytokine milieu and the epigenetic environment for the activities they are programmed to exhibit.
As is increasingly evident, the fate decisions may not be unidirectional or terminal, but the cells can undergo transcriptional reprogramming exhibiting different effector functions.
In this section, we focus on the contribution of type 2 cytokineproducing CD4 + T cells in the development of asthma. Differentiation into Th2 cells is dependent on the cytokine IL-4 followed by the expression of the key transcription factor GATA3. Th2 cells release IL-4
and IL-13 which promote IgE production in human B cells, and growth and differentiation of human B cells and monocytes. 28 Th2 cells protect against nematodes but also play a central role in allergic immune responses. 29, 30 Based on in vitro and in vivo studies in mice as well as in humans, the processes of Th1/Th2 polarization in CD4 + T cells is reciprocally regulated. [31] [32] [33] The expression of the key type 1 transcription factor T-BET and production of IFNγ do not only lead to the differentiation of Th1 cells but also exerts an inhibitory function on the maturation of Th2 cells. 28 Likewise, GATA3 expression and the presence of IL-4 favor Th2 polarization, but additionally inhibit the differentiation of Th1 cells. 28 The differentiation of Th2 cells is highlighted by molecular events leading to the activation of the IL-4/IL-13 pathway. [34] [35] [36] [37] IL-4 binds to a receptor composed of an IL-4Rα chain and the common γ chain, inducing oligomerization. IL-13 binds to its own specific receptor subunit IL-13Rα1 chain to which IL-4 cannot bind, and additionally to the IL-4Rα chain (IL-4 receptor α). 38 IL-4 activates the Janus tyrosine kinases (JAK1 and JAK3), while IL-13 transmits its signal through JAK1 and the Tyk2 kinase. The activated kinases initiate the phosphorylation of the intracellular molecule signal transducer and activator of transcription 6 (STAT6).
Once phosphorylated, STAT6 forms homodimers which translocate to the nucleus and bind to IL-4/IL-13 responsive regulatory gene regions.
The pathophysiological importance of type 2 cytokine production has been demonstrated in several studies as increased levels of IL-4, IL-5, and IL-13 were observed in asthmatic patients. [39] [40] [41] [42] [43] [44] Mice lacking IL-4Rα were also unable to develop AHR, induce mucus production, or airway inflammation.
| The role of CD4 + T cells in experimental asthma
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The JAK-STAT signaling pathway is involved in many of the physiologic events that are dysregulated in asthma which is why this pathway has been targeted in various immune disorders. 63 Only a few studies have investigated the effects on asthma pathogenesis after inhibition of the JAK pathway. Using the JAK1 and JAK3 inhibitor R256, the in vitro differentiation of Th2 cells was prevented by blocking the phosphorylation of STAT6 and STAT5 without affecting Th1 and Th17 differentiation. 64 Lung allergic responses including AHR, eosinophilia, airway inflammation, and Th2 cytokine production in the BAL fluid were prevented in a model of experimental asthma when R256 was administered during the sensitization phase. 64 As shown in vitro, cytokine release by Th1, Th17, and Treg cells in the BAL fluid remained unaltered in R256-treated mice in response to allergen sensitization and challenge. 64 When mice were treated with R256 during the challenge phase in an acute model or a secondary allergen challenge model, AHR, eosinophilia, and goblet cell metaplasia were significantly attenuated. 64 However, Th2 cytokine levels including IL-4, IL-5, and IL-13 in the BAL fluid were not reduced in response to R256 treatment during the challenge phase in both models suggesting that the inhibitory effects were limited to an early stage of Th2 polarization and potentially downstream of the Th2 cytokine receptor signaling pathway. 64 Other drugs (tofacitinib, pyridine 6) targeting the JAK family members have been reported to reduce lung allergic responses in vivo. 65, 66 BAL cells from asthmatics and healthy controls cultured in the presence of tofacitinib alone or in combination with the corticosteroid dexamethasone (DEX) decreased the production of IFNγ, IL-13, and IL-17. 67 Unlike R256, these pan-JAK inhibitors also altered Treg, Th1, and Th17 responses.
Naive cells from mice lacking STAT6 were not capable of differentiating into Th2 cells. [68] [69] [70] Following allergen sensitization and challenge, STAT6-deficient mice failed to develop AHR and airway eosinophilia. 71, 72 Consistent with these observations, lower levels of the Th2 cytokines IL-4 and IL-5, but increases in the Th1 cytokine IFNγ were detected. 72 Moreover, total serum and ovalbumin (OVA)-specific IgE production were completely abolished accompanied by significantly increased IgG2a responses in the serum and increased IFNγ levels in the BAL fluid. Following reconstitution with IL-5, AHR and airway eosinophilia were similar to WT mice. 72 Of note, STAT6-deficient mice receiving IL-5 still developed a Th1 response after sensitization and challenge as reflected by high IFNγ and IgG2a production paralleled by low levels of IL-4 and the absence of goblet cell metaplasia, total IgE, and OVA-specific IgE. 72 Another gene regulated through the JAK/STAT pathway is the serine/threonine kinase Pim1 whose activity can be induced by type 2 cytokines. The role of PIM1 kinase has mainly been studied in tumor pathogenesis, [73] [74] [75] [76] [77] but the expression of Pim1 was critical to the IL-5-induced survival of eosinophils 78, 79 and promoted cell survival in T cells. 80 Further, PIM1 expression was elevated in BAL eosinophils compared to blood cells from asthmatics in response to in vitro allergen exposure. 81 Levels of PIM1 kinase were increased in the lungs of sensitized and challenged mice. 82 To determine the role of PIM1 kinase in experimental asthma, mice were treated with a PIM1 kinase inhibitor during the challenge phase resulting in dose-response outcomes with significantly lower BAL eosinophil numbers, goblet cell metaplasia, AHR, and BAL cytokine levels including IL-4, IL-5, IL-13,
and IFNγ in comparison with sham-treated mice. 82 Interestingly, CD4 + and CD8 + T-cell numbers in the lungs were significantly diminished in response to in vivo treatment with the inhibitor during the challenge phase. 82 In vitro cultures confirmed these findings with reduced proliferative responses of both T-cell subsets in response to T-cell receptor (TCR) stimulation (anti-CD3/CD28) combined with the PIM1 kinase inhibitor, leading to lower cytokine production of IL-4, IL-5, IL-13, and
IFNγ in the supernatants of cultured cells. 82 Based on the findings on the pharmacological inhibition of PIM1 kinase activity in an allergeninduced model of experimental asthma, de Vries and colleagues investigated whether PIM1 kinase activity protects against the development of HDM-induced allergic asthma in vivo by preserving airway epithelial integrity. 83 PIM1-deficient mice demonstrated a similar increase in lung allergic responses including eosinophilia, mucus production, and AHR in comparison with WT mice exposed to HDM, while the Th2 cytokines IL-5 and IL-10 were significantly increased in HDMtreated PIM1-deficient mice. 83 Albeit in a relatively small population, primary bronchial epithelial cells (PBEC) from healthy controls and moderate/severe asthmatics cultured by air-liquid interface suggested that the inhibition of the PIM1 kinase reduced the viral load of cells infected with human rhinovirus (HRV) in both the healthy controls and asthmatics. 84 Analyses of the expression of IFNβ and IL-29 showed strongly enhanced mRNA levels upon HRV infection compared with mock-infected control PBEC in healthy controls accompanied by enhanced STAT1 phosphorylation which was further enhanced in the presence of the PIM1 kinase inhibitor. 84 An important relationship exists between PIM1 kinase and the Runt-related transcription factor (Runx 
| LTB4-BLT1 pathway in CD8 + T-cell activation
BLT1 is a high-affinity receptor specific for LTB4, whereas BLT2 is a low-affinity receptor which also binds other eicosanoids. These two receptors differ in their expression pattern: BLT1 is expressed primarily on leukocytes, whereas BLT2 is expressed more ubiquitously.
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LTB4 was described as a chemoattractant for myeloid leukocytes, 142, 143 while BLT1 was shown to be expressed on granulocytes, macrophages, monocytes, and eosinophils and to a lesser extent on naive lymphocytes. 141,144-147 BLT1 also acts as an important attractant for differentiated T cells and BLT1 expression was increased on mouse CD4 + T cells that have been differentiated in vitro to effector phenotypes. 148 In vitro, activated CD4 + T cells cultured under non-(Th0), Th1-, or Th2-polarizing conditions all had increased levels of mRNA encoding Blt1 compared with naive cells, which expressed little Blt1. 148 In contrast, expression of BLT2 on naive T cells or on Th0, Th1, or Th2 effector cells was not detected. BLT1 expression was induced in CD4 + T cells leaving the lymph node and entering the tissue after activation by antigen. 148 Similarly, BLT1 expression on mouse CD8 + T cells following in vitro differentiation to effector phenotypes has been shown.
149,150
The LTB4-BLT1 pathway appears to play an important role in the recruitment and activation of IL-13-producing CD8 + Teff in the lung ( Figure 1 ). In vitro-generated CD8 + Teff expresses higher mRNA levels of the LTB4 high-affinity receptor, Blt1, than CD8 + Tcm. 149, 150 To investigate whether BLT1 expression was essential for the devel- recipients. 151 Initially, it was reported that trafficking of Teff into the airway did not differ in the presence or absence of this receptor following adoptive transfer and airway challenge of naive (non-sensitized) recipients. 148 However, using sensitized and challenged mice as opposed to naive recipient mice, migration of transferred BLT1 −/− Teff into the lung as well as BAL fluid was significantly impaired compared with transferred BLT1 +/+ Teff. 151 As recipient mice were sensitized to OVA prior to OVA challenge, LTB4 production in the lungs was shown to be significantly higher than levels in recipients that were non-sensitized and challenged only. 152 The increased levels of LTB4 played a pivotal role in enhancing the recruitment of transferred BLT1 +/+ Teff into the lung. In a different lung disease model, BLT1 was shown to contribute to the development of lung rejection and obliterative bronchiolitis by mediating effector CD8 + T-cell trafficking into the lung. 153 Different members of the chemokine family are known to be subset-selective chemoattractants for T cells. CCL2 and CCL5 may be important in the recruitment of CD8 + T cells. 116 CD8 + Teff were reported to migrate in response to CCL5 as well as LTB4 in vitro. 154 It appears that the LTB4-dependent pathway and signals contribute at least one essential link to a chain of molecular events that lead to efficient recruitment of CD8 + Teff to the allergic airways ( Figure 1 ).
| The IgE-FcεRI-mast cell-CD8-BLT1-IL-13 connection
Many of the studies carried out in mice utilized systemic sensitization and challenge. This experimental model was shown to be (relatively) IgE-and mast cell-independent as mast cell-deficient mice and B-cell-deficient mice developed comparable levels of airway allergic responses as control littermates. 155, 156 To compare different approaches, responses in a well-characterized mast cell-dependent system were examined. In this model, CD8 + T cells were shown to be required for development of altered airway responsiveness. 157 Briefly, following 10-day allergen exposure via the airways (in the absence of systemic sensitization with alum), FcεRI-deficient mice failed to develop altered airway function, with less airway inflammation and lower IL-13 levels. These results were further confirmed using leukotriene A4 hydrolase (LTA4H)-deficient mice which failed to synthesize LTB4. 160 The role of this lipid mediator was investigated in allergen-induced airway alterations using two approaches. First, LTA4H-deficient and WT mice were systemically sensitized and challenged to allergen via the airways (mast cell-independent). Second, the animals were initially passively sensitized with OVA-specific IgE, followed by challenge with OVA via the airways (mast cell dependent). In both approaches, LTA4H-deficient mice developed little AHR and eosinophilia, and IL-13 levels in the BAL fluid were significantly lower compared with WT mice.
Transfer of LTA4H +/+ but not LTA4H −/− BMMC into LTA4H-deficient mice reconstituted AHR and lung allergic responses in passively sensitized recipients.
Although the importance of LTB4 in allergic airway disease and T-cell activation was suggested over two decades ago, 145 the role of LTB4 in the recruitment of antigen-specific effector CD8 + T cells in both mast cell-dependent and cell-independent allergic airway responses underscores how control of this LTB4-BLT1 pathway may provide novel therapeutic opportunities for the treatment of asthma. Alterations in H3K4me3, H3K27me3, and histone acetylation regulate CD8 + T-cell memory development, [165] [166] [167] [168] and permissive histone modifications poise cytokine gene promoters for rapid transcription after stimulation. Little is known about the interrelationships of histone regulation, asthma pathophysiology, and CD8 + T-cell plasticity as opposed to fixed lineage commitment.
| Transcriptional reprogramming of CD8
We proposed that antigen-specific CD8 + T cells committed to IFNγ production, when exposed to IL-4 in vitro or an atopic environment, transit through distinct differentiation stages characterized by changes in transcription and translation resulting in IL-13-producing CD8 + T cells. 100 In a different system, Hayashi et al. 169 showed that Th1 cells, committed to IFNγ production, can also convert to Th2 cytokine production such as IL-13 under specific conditions. As reviewed by O'Shea and Paul, 162 it is still unclear what is meant by the terms lineage stability and plasticity/conversion, and how they can be distinguished. 
| Steroid insensitivity of CD8 + T cells
Corticosteroids effectively suppress inflammatory responses through repression of many immune genes through interactions with the glucocorticoid receptor. To some extent, this explains the benefits in many patients with asthma, but not in those asthmatic patients who suffer a decrease in lung function despite high doses of inhaled or oral corticosteroid treatment. [170] [171] [172] Paradoxic effects of corticosteroids on neutrophils, such as increased LTB4-induced intracellular Ca 2+ mobilization, chemotaxis, and enhanced survival, have been reported. 173, 174 These effects were mediated through upregulation of BLT1 expression, a major neutrophil chemoattractant receptor. 173, 174 Susceptibility to corticosteroids differs among T-cell subpopulations and states of maturity. proposed to represent an example of a "steroid-insensitive" pathway.
Enhancement or amplification of the LTB4/BLT1 pathway by corticosteroids represents a potentially important negative factor in asthmatic patients receiving high doses of inhaled or oral corticosteroids.
Glucocorticoid insensitivity of lymphocytes has also been described in a number of human diseases. 
| Role of CD8 + T cells in human asthma
Whereas the studies in experimental asthma enable manipulation and As discussed, CD8 + T-cell expansion, especially in SR asthma, was relatively resistant to corticosteroids compared with CD4 + T cells. The pathway leading to the generation of lipid mediators, including LTB4, is activated in many inflammatory diseases but is resistant to corticosteroid treatment. 194 The generation of LTB4 appears to be an important contributor to SR asthma as confirmed in this study. 
| Regulation of lung allergic responses by nTregs
To assess the importance of nTregs in the development of lung aller- 
| nTregs attenuate mast cell-dependent lung allergic responses
Given that changes in function and structural thickening of airway recipients. IL-6 is a proinflammatory cytokine that plays a prominent role in host defense and response to injury. 249 The combination of IL-6
and TFG-β is central to the differentiation of Th17 cells. 250 Similar to nTregs from CD8-deficient mice, IL-6-treated nTregs from WT donors failed to decrease lung responses in recipients which was consistent with other studies. [251] [252] [253] In contrast, interference with IL-6 activity by administering anti-IL-6 or genetic depletion of IL-6 restored suppression of lung responses in recipients given nTregs from CD8-deficient or IL-6-deficient mice. 238 Collectively, these data demonstrated the inhibitory effects of endogenous or exogenous IL-6 on nTreg function leading to reduced Foxp3 expression and suppressive activities.
| Functional reprogramming of nTregs
The variable effector functions of nTregs, dependent on environmental cues, suggested an ability to undergo transcriptional reprogramming, the underpinning of plasticity. 256 Prior to these reports, nTregs were thought to be terminally differentiated, consistent with the concept of unidirectional lineage commitment. In the absence of CD8, the functional development of nTregs was altered in that they were unable to prevent the development of lung responses in sensitized and challenged WT recipients. 
| Role of iTregs cell activities in experimental asthma
In contrast to nTregs, iTregs appear to be antigen-induced and derived differently, but share many features. iTregs were generated in vitro by culturing activated (anti-CD3/CD28) Foxp3 
| Role of Tregs in human asthma
The importance of Tregs in man is underscored by their absence and consequences in the IPEX syndrome. 203 However, except for a few reports, [265] [266] [267] (mTregs), which display differences not only in phenotype but also in function and behavior. 272 In contrast to CD45RA + Tregs, CD45RO + Tregs were reported to be more suppressive, 273 but were prone to acquire effector function, secreting IL-17 in vitro. 268 The eTregs were capable of greater expansion than nTregs, and fewer genes were detected by microarray gene expression analysis of nTregs when compared with eTregs. 273 ICOS + eTregs preferentially expressed IL-10 274 and suppressor function of BAL fluid-derived Tregs was dependent on TGF-β. 265 Similar to mouse, regulatory functions and phenotypes of human Tregs were directly correlated to the expression and activity levels of Foxp3. 281 Lack of suppression was also reported in activated TCR-induced expression of FOXP3 in human cells, [269] [270] [271] suggesting that other molecular mechanism(s) may be required for endowing regulatory function. Although both mouse iTregs and nTregs retained the capacity to undergo transcriptional reprogramming and conversion into pathogenic effector T cells, it is unclear whether human Tregs possess a similar plasticity in vivo and is an important consideration in the development of Treg-based therapy.
| GAMMA-DELTA (γδ) T CELLS IN EXPERIMENTAL AND HUMAN ASTHMA
γδ T cells are a small subset which develop in the fetal thymus and primarily localize in mucosal tissues such as lung, skin, uterus, and intestine in mice. 282 Long-term or repeated allergen exposure has been shown to induce resolution of AHR and airway inflammation in allergen-sensitized mice. 289 In this setting, Vγ4 + T cells were shown to play a key role in the resolution of AHR, which was independent of induction of antigenspecific tolerance of αβ T cells. 289 Functional differentiation of these suppressive Vγ4 + T cells required antigen stimulation, whereas they still suppressed AHR without antigen stimulation once suppressive activities of the cells were induced. 290 Induction of suppressive Vγ4 + T cells required CD8 + DCs in the lymphoid tissues, and the effects were triggered through direct cell-cell contact. 
| Natural killer T (NKT) cells in experimental and human asthma
iNKT cells, also present in small numbers, have been linked to the pathogenesis of asthma, in large part because they can rapidly release large amounts of cytokines and chemokines following activation by glycolipids, many of which are found in microorganisms. 300 To date, controversy remains about the role and magnitude of the contributions of iNKT cells within the lungs of asthmatics. [301] [302] [303] We suggested this variability could be due to a functional plasticity within the iNKT subset. 304 We demonstrated that IFNγ played a critical role in dictating the consequences of iNKT cell activation to become either IFNγ or IL-13 producers in the initiation phase of the development of AHR and airway inflammation. 304 In experimental asthma, iNKT cells were shown to enhance Th2 responses through adjuvant effects and obesity-induced functional upregulation of iNKT cells, which augmented Th2 cytokine responses. 305, 306 Whether iNKT cells are activated in asthmatics and whether the pathogenic effects of activated iNKT cells that were observed in mice are reproducible in human asthma remain to be determined. 307 
| TRANSCRIPTOMIC PROFILING OF IMMUNOLOGICALLY RELEVANT SPECIMENS CONTRIBUTING TO ASTHMA
To determine whether the clinical heterogeneity of asthma is also reflected in underlying molecular mechanisms, global gene expression profiles have been monitored in human asthmatics including isolated leukocyte populations, [308] [309] [310] [311] bronchial and epithelial biopsies, [312] [313] [314] [315] [316] and nasal lavage samples. 317 Comparing asthmatics and healthy controls, two distinct subgroups of patients were identified with a "Th2 high" or a "Th2 low" transcriptomic profile with key markers of asthma including levels of IL-5 and IL-13, AHR, serum IgE, blood and airway eosinophilia, subepithelial fibrosis, airway MUCIN gene expression, and improvement with inhaled corticosteroids. 5 A signature of IL-13-induced genes including PERIOSTIN, CLCA1, and SERPINB2 correlated with the "Th2 high" group. 5 These studies provided mechanistic insights into mild-to-moderate and atopic asthma. Further clustering based on transcriptomic endotypes of asthma (TEA) was performed in the sputum and blood of patients with asthma identifying three major with SR asthma. 321 In a large cohort including 1170 asthmatic adults from the Asthma BioRepository for Integrative Genomic Exploration (Asthma BRIDGE) and the Childhood Asthma Management Program study, transcriptomic profiles were analyzed in whole blood and CD4 + T cells to assess the relationship to chronic and acute asthma control. 322 In the initial discovery cohort using whole blood samples, 1106
genes were found to be significantly overrepresented and associated with asthma control; 53% of these were replicated in at least one of the three replication cohorts determining gene expression signatures in either whole blood or CD4 + T cells. These studies identified eosin- (Table 1 ). In order to address the multifactorial entities of asthma, future investigations need to be developed in well-phenotyped populations with cohort-specific definitions of optimal asthma control and steroid responsiveness.
In addition, this must be coupled with sampling of different immunologically relevant specimens from the same patient at multiple time points to delineate the longitudinal contributions to disease pathogenesis. Adding to the complexity is that regulatory regions of genes, in spite of being epigenetically poised for expression, may not be actively transcribed until an appropriate environmental signal is received.
Therefore, coupling transcriptomic analyses at baseline and after activation may be necessary to identify regulatory regions that control expression of genes relevant to severe asthma. Further, integration of different "omics" datasets including genetics, genomic, proteomic, and metabolomics will provide a unique opportunity to identify true causal genes and endotypes responsible for the disease.
| ROLE OF THE STEROIDOGENIC ENZYME CYP11A1 IN ASTHMA PATHOBIOLOGY
The cholesterol side-chain cleavage P450 enzyme (CYP11A1) is a key regulator of steroid biogenesis as the first and rate-limiting enzyme in the steroidogenic pathway converting cholesterol to pregnenolone.
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CYP11A1 is expressed primarily in the cortex of the adrenal gland, testis, ovary, placenta, and thymus. [323] [324] [325] CYP11A1 is also expressed in various non-endocrine tissues, including the lung, spleen, intestine, stomach, liver, brain, and kidney. [323] [324] [325] Activation of CYP11A1 results in a spectrum of steroid hormones, including glucocorticoids that are known to play a role in T-cell function. 325, 326 In humans, mutations in the CYP11A1 gene result in steroid hormone deficiency and can cause the rare and potentially fatal condition, lipoid congenital adrenal hyperplasia. [327] [328] [329] Patients with a heterozygous or homozygous mutation of CYP11A1 exhibit adrenal insufficiency and sex reversal. 330, 331 Depletion of Cyp11a1 in mice or rabbits results in steroid deficiency, female external genitalia, and death. 326, 332, 333 During the differentiation of CD8 + T lymphocytes to a Tc2 phenotype, transcriptional profiling identified a marked upregulation of mRNA levels remained unaffected after silencing of Cyp11a1. 339 These data indicate that CYP11A1 critically regulates Th2 and Tc2 cell differentiation and type 2 cytokine production in both T-cell subsets downstream of the essential lineage-specific transcription factor Gata3.
Recently, we identified a novel regulatory mechanism mediated through CYP11A1 which promoted IL-4-induced CD8 + T-cell conversion to IL-13 production. 340 gene expression. 340 Translating findings from the mouse model of experimental asthma to human studies provided a unique tool to identify similar mechanistic links between the steroidogenic enzyme CYP11A1
as a key regulator of CD8 + Tc2 and CD4 + Th2 cell transcriptional programming and plasticity and susceptibility to childhood asthma.
| CONCLUSIONS
Asthma is a common chronic disease of the airways and continues to challenge both clinicians and researchers. The search for common genetic factors is stymied by the number of triggers, epigenetic con- 
